SCHEMBL792915

SCHEMBL792915

Fc1c(I)ccnc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30340481 1.00
SCHEMBL30296911 0.75
SCHEMBL144072 0.75
SCHEMBL29506145 0.75
SCHEMBL6347184 0.75
SCHEMBL29572371 0.75
SCHEMBL541874 0.75
SCHEMBL564546 0.75
SCHEMBL28459550 0.75 AAK1 (0.40)
SCHEMBL28391211 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111620811-B Novel liquid crystal raw material, chiral catalyst ligand compound and synthesis method thereof 河北松辰医药科技有限公司 2021-11-05 CN claimed
CN-111620811-A Novel liquid crystal raw material, chiral catalyst ligand compound and synthesis method thereof 河北松辰医药科技有限公司 2020-09-04 CN claimed
EP-4737450-A1 HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE Longwood Pharmaceuticals (Hangzhou) Co., Ltd (CN) 2026-05-06 EP disclosed
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-04-16 US disclosed
EP-4720057-A2 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2026-04-08 EP disclosed
EP-4178620-B1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-01 EP disclosed
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-02-26 US disclosed
US-12528826-B2 [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2026-01-20 US disclosed
US-12528786-B2 Plasma kallikrein inhibitors MERCK SHARP & DOHME LLC (US) 2026-01-20 US disclosed
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 US disclosed
US-20250304549-A1 HYDROXYAMIDE DERIVATIVE AND USE THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2025-10-02 US disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
WO-2012080284-A2 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2012-06-21 WO disclosed
WO-2012035039-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-03-22 WO disclosed
WO-2012035039-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-03-22 WO disclosed
WO-2012002577-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF 富士フイルム株式会社 (JP) 2012-01-05 WO disclosed
WO-2009117421-A2 HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-09-24 WO disclosed
WO-2009117421-A2 HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-09-24 WO disclosed